Home  /  Resource Library  /  Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: a single-institution experience

Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: a single-institution experience

Results of a retrospective study comparing yttrium-90 ibritumomab tiuxetan with rituximab maintenance for treatment of indolent lymphomas.